Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 409

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 409
---
:                                                                            |       |        |       |
| •Change in fair value (excluding investments accounted for using the equitymethod)(b)                                     |     5 |     21 |   -77 |
| •Tax effects                                                                                                              |     — |     -4 |    15 |
| Cash flow and fair value hedges:                                                                                          |       |        |       |
| •Change in fair value (excluding investments accounted for using the equitymethod)(c)                                     |    -3 |      1 |     5 |
| •Change in fair value (investments accounted for using the equity method,net of taxes)                                    |    -3 |     -2 |     2 |
| ▪Tax effects                                                                                                              |     2 |      — |    -1 |
| Change in currency translation differences:                                                                               |       |        |       |
| •Currency translation differences on foreign subsidiaries (excluding investmentsaccounted for using the equity method)(d) | 2,560 | -1,551 | 2,643 |
| •Currency translation differences (investments accounted for using the equitymethod)(d)                                   |     3 |      3 |   -11 |
| •Hedges of net investments in foreign operations(d)                                                                       |  -121 |      8 |  -354 |
| •Tax effects                                                                                                              |    17 |     -2 |    91 |
| Items subsequently reclassifiable to profit or loss(e)                                                                    | 2,460 | -1,526 | 2,313 |

(a) Items not subsequently reclassifiable to profit or loss and attributable to Opella: € ( 1) million in 2024, immaterial amount in 2023 and € 20million in 2022.

(b) Amounts reclassified to profit or loss were immaterial in 2024 , 2023 and 2022 .

(c) Amounts reclassified to profit or loss: € 1million in 2024 , € 1million in 2023 and € 2million in 2022 .

(d) Amounts reclassified to profit or loss: € 5million in 2024 , € ( 56) million in 2023 and € ( 40) million in 2022 (including € ( 35) million relating to the

deconsolidation of EUROAPI). Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries,

and are mainly due to